TICKERNERD
Menu
OMCLOMCLHealthcare · Health Information Services

OMCL Stock Forecast: Omnicell, Inc. Price Predictions for 2026-2027

Last close, 17 Sept 2026
$33
+0.59% on the day

The 8 Wall Street analysts covering Omnicell, Inc. hold a median 12-month price target of $60 — +83.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 17 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.5B
Ticker Nerd rank
96 / 100
Median analyst target
$60
Analysts covering
8
Revenue$312.2M+7.4% y/y
Operating income$32.4M
Net income$24.3M
Free cash flow$55.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.1%
1M
−9.5%
YTD
−28.0%
1Y
+4.6%
From 52W high
−36.5%
From 52W low
+10.7%
$29
$51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OMCL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Omnicell, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Sept 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Issuance
96
Accruals
86
Revisions
77
Growth
72
Quality
69
Volatility
54
Momentum
49
Size
39

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (49): The shares have been drifting down relative to others.

Size (39): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OMCL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OMCL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26OMCLHigh $70Median $60Low $45

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $45Median $60High $70

The green dot is the last close — the median target sits +83.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
3 Aug 2026Piper SandlerReiteratesOverweight$55 → $45
31 July 2026KeybancMaintainsOverweight$70 → $65
31 July 2026Wells FargoMaintainsOverweight$55 → $50
29 Apr 2026KeybancMaintainsOverweight—
29 Apr 2026KeybancMaintainsOverweight$60 → $70
23 Apr 2026Wells FargoMaintainsOverweight—
23 Apr 2026Wells FargoMaintainsOverweight$52 → $55
6 Feb 2026Piper SandlerReiteratesOverweight—
2 Feb 2026BenchmarkMaintainsBuy—
8 Jan 2026KeybancUpgradeOverweight—
5 Jan 2026Wells FargoMaintainsOverweight—
9 Dec 2025B of A SecuritiesMaintainsNeutral—
9 Dec 2025BenchmarkMaintainsBuy—
31 Oct 2025BenchmarkMaintainsBuy—
11 Aug 2025Piper SandlerMaintainsOverweight—
21 July 2025Wells FargoMaintainsOverweight—
14 July 2025B of A SecuritiesMaintainsNeutral—
23 May 2025B of A SecuritiesMaintainsNeutral—
23 May 2025Wells FargoMaintainsOverweight—
14 May 2025Wells FargoUpgradeOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OMCL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OMCL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Sept 2026, Omnicell, Inc. returned +4.6% against +17.0% for the S&P 500, dividends included.

OMCL vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160Oct 25Jan 26Apr 26Jul 26OMCLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OMCL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+17.1%
Analysts raising
6
Analysts cutting
0
Fundamentals

Omnicell, Inc. (OMCL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
39.1×

Cheaper than 19% of US stocks

Price / sales
1.2×

Cheaper than 65% of US stocks

Price / book
1.1×

Cheaper than 68% of US stocks

EV / EBITDA
16.9×

Cheaper than 19% of US stocks

Growth & margins
Revenue growth (YoY)
7.5%

Higher than 45% of US stocks

Earnings growth (YoY)
330.7%

Higher than 93% of US stocks

Gross margin
49.0%

Higher than 61% of US stocks

Operating margin
5.9%

Higher than 57% of US stocks

Net margin
3.1%

Higher than 55% of US stocks

Returns & dividend
Return on equity
3.1%

Higher than 50% of US stocks

Return on assets
1.5%

Higher than 55% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Omnicell, Inc. (OMCL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Omnicell, Inc. has a market value of $1.5B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter grew 7.5% year on year.

  • Net income over the same four quarters: $39.1M, a 3.1% net margin.

  • Diluted earnings per share, trailing twelve months: $0.84.

  • Free cash flow in the twelve months to 30 June 2026: $126.8M.

  • Shares outstanding: 45.6M.

  • Trailing P/E: 39.1×; forward P/E: 15.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Omnicell, Inc. employs 3,485 people — $358K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Sept 2026

Data provided by Twelve Data

Peers

OMCL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
OMCLOmnicell, Inc.$1.5B
96
CERTCertara, Inc.$1.4B
56
OMDAOmada Health, Inc.$1.2B
83
GDRXGoodRx Holdings, Inc.$1.2B
78
TDOCTeladoc Health, Inc.$1.1B
66
SDGRSchrödinger, Inc.$2.3B
55
PRVAPrivia Health Group, Inc.$2.5B
66

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Omnicell, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OMCL news & analysis

Here's Why Omnicell (OMCL) is a Strong Value Stock

Zacks Investment Research · 16 Sept 2026positive

Zacks Investment Research highlighted Omnicell (OMCL) as a strong value stock using its Zacks Style Scores, which help investors identify strong, market-beating stocks for their portfolios. The article points to Omnicell's favorable value characteristics.

Why it matters — OMCL watchers would note that the stock has been flagged by Zacks' Style Scores as a strong value pick, which could attract additional investor attention.

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

PRNewsWire · 3 Sept 2026neutral

TraceLink and Omnicell have integrated their DSCSA compliance solution into hospital pharmacy operations, bringing serialized product verification and traceability directly into medication receiving workflows. The integration is intended to enable more efficient pharmacy operations without requiring separate compliance processes.

Why it matters — OMCL watchers would care because this integration could streamline pharmacy compliance workflows and potentially strengthen Omnicell's product offering within hospital pharmacy operations.

Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference

Business Wire · 31 Aug 2026neutral

Omnicell announced it will present at the Wells Fargo 21st Annual Healthcare Conference. The announcement, which comes from a Business Wire release based in Fort Worth, Texas, confirms the company's participation in the upcoming healthcare industry event.

Why it matters — A presentation at a major industry conference gives OMCL watchers an opportunity to hear company updates and management remarks in a prominent healthcare-sector setting.

Why Omnicell (OMCL) is a Top Value Stock for the Long-Term

Zacks Investment Research · 24 Aug 2026positive

Zacks Investment Research highlights Omnicell (OMCL) as a top value stock for the long term, citing its Style Scores system as a way to identify top-rated stocks based on investing style.

Why it matters — OMCL watchers would care because the piece signals that the stock ranks favorably in Zacks' value-oriented screening methodology, potentially supporting long-term investor interest.

Omnicell President Sells 6,753 Shares

The Motley Fool · 20 Aug 2026neutral

Omnicell's president sold 6,753 shares in a transaction valued at roughly $250,000, reducing the insider's direct equity holdings by 4%.

Why it matters — A reduction in direct holdings by Omnicell's president offers OMCL watchers insight into insider selling activity at the company.

FAQ

Frequently asked questions about OMCL stock

What is the OMCL stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Omnicell, Inc. have a median 12-month price target of $60, with estimates ranging from $45 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OMCL stock a buy right now?

Of the 8 analysts covering Omnicell, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Omnicell, Inc. 96 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OMCL?

As at 17 Sept 2026, Omnicell, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will OMCL stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +83.9% from the last close, and Ticker Nerd's factor model ranks Omnicell, Inc. 96 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OMCL stock forecast for 2030?

No analyst covering Omnicell, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OMCL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $70 over the next 12 months.

How has OMCL stock performed over the past year?

Omnicell, Inc. returned +4.6% over the 12 months to 17 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Omnicell, Inc. do?

Omnicell, Inc. is a healthcare technology company that provides medication management solutions and adherence tools for hospitals, health systems, retail pharmacies, and other care settings.

What is the latest news on OMCL?

The most recent item we track (Zacks Investment Research, 16 Sept 2026): "Here's Why Omnicell (OMCL) is a Strong Value Stock". Zacks Investment Research highlighted Omnicell (OMCL) as a strong value stock using its Zacks Style Scores, which help investors identify strong, market-beating stocks for their portfolios. The article points to Omnicell's favorable value characteristics.

Company

About Omnicell, Inc.

Omnicell, Inc. is a healthcare technology company that provides medication management solutions and adherence tools for hospitals, health systems, retail pharmacies, and other care settings. Omnicell’s portfolio includes automated dispensing systems, central pharmacy automation, robotic dispensing, IV compounding, inventory management software, and point-of-care solutions designed to streamline medication workflows and support safer medication handling. The company also offers patient engagement and medication adherence tools through its EnlivenHealth brand, helping pharmacies and providers manage prescriptions, packaging, and communication more efficiently. Omnicell’s products and services are used across inpatient, outpatient, post-acute, and retail environments, where they support clinical teams with automation, analytics, and workflow integration. The company plays a notable role in healthcare operations by helping organizations improve medication management across the care continuum.

CEO Mr. Randall A. Lipps · 3,485 employees · United States · https://www.omnicell.com